There are 398 resources available
Invited Discussant 59MO, 60MO, 91MO and 92MO
Presenter: Janice Wing-Hang Tsang
Session: Mini Oral session 1
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mini Oral session 1
Resources:
Webcast
93MO - Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial
Presenter: Géraldine Gebhart
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 93MO
Presenter: Alessandra Gennari
Session: Mini Oral session 1
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mini Oral session 1
Resources:
Webcast
If your premenopausal patient with ER+ early breast cancer requires OFS, do you always combine it with an aromatase inhibitor? YES
Presenter: Olivia Pagani
Session: YOC boxing session
Resources:
Slides
Webcast
If your premenopausal patient with ER+ early breast cancer requires OFS, do you always combine it with an aromatase inhibitor? NO
Presenter: Matteo Lambertini
Session: YOC boxing session
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: YOC boxing session
Resources:
Webcast
Do you still think that anthracycline-based chemotherapy is needed in your clinical practice for patients with early breast cancer? YES
Presenter: Alexios Matikas
Session: YOC boxing session
Resources:
Slides
Webcast
Do you still think that anthracycline-based chemotherapy is needed in your clinical practice for patients with early breast cancer? NO
Presenter: Sabine Linn
Session: YOC boxing session
Resources:
Slides
Webcast